Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

Citation
B. Guy et al., Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine, VACCINE, 19(13-14), 2001, pp. 1794-1805
Citations number
38
Categorie Soggetti
Veterinary Medicine/Animal Health",Immunology
Journal title
VACCINE
ISSN journal
0264410X → ACNP
Volume
19
Issue
13-14
Year of publication
2001
Pages
1794 - 1805
Database
ISI
SICI code
0264-410X(20010208)19:13-14<1794:DCAPEO>2.0.ZU;2-I
Abstract
We prepared a series of cationic lipid vesicles comprising a cationic chole sterol derivative, DC-Chol with or without a neutral phospholipid, DOPC or DOPE. The vesicles were tested for their ability to bind and adjuvant split inactivated influenza vaccines. We found that DC-Chol-containing liposomes are capable to strongly bind influenza vaccine antigens upon simple mixing with the vaccine. The resulting formulations induced robust anti-influenza immune responses both after s.c. and i.n. administration in BALB/c mice wh ile neutral Cholesterol/DOPC liposomes displayed virtually no stable antige n binding and no adjuvant effect. The parenteral adjuvant effect of DC-Chol on trivalent split influenza vaccines was then confirmed in outbred mice a nd monkeys. Among the most potent formulations tested, a simple mixture of the vaccine with a microfluidized dispersion of DC-Chol in an aqueous buffe r is being considered for further development to produce an improved influe nza vaccine. (C) 2001 Elsevier Science Ltd. All rights reserved.